2076975 2077203
최종편집 2020-10-26 06:23 (월)
Slump of foreignㆍlarge companies in the outpatient market 
상태바
Slump of foreignㆍlarge companies in the outpatient market 
  • Hyeokgi Lee, Newsmp
  • 승인 2020.09.29 15:35
  • 댓글 0
이 기사를 공유합니다

Growth rate of foreign affiliates -2.45%... -3.3% for $10 million corporations 
Under $10 million domestic companies +2.81% … around $10 million + 1.22%

In the aftermath of COVID-19, the outpatient market has weakened significantly, particularly foreign affiliates and top companies. 

According to recent trend of the outpatient report, the total amount of prescription of 36 companies, which recorded an average of over $10 million monthly until August, has reduced 0.27% YoY to $6.947 billion.

However, during the same period, 2.05% has increased to $3.7929 billion for under $10 million.

The amount of outpatient prescription was $9.8876 billion, with a growth rate of 0.61% YoY, due to a stagnation of $10 million corporations that possess more than half of the prescription amount. 

Although the total prescription amount has advanced for domestic companies to $7.55 billion, up 1.89%, the foreign affiliates dropped 2.45% to $3.9577 billion.

The combined prescription amount for domestic companies with a monthly prescription amount of over $10 million was $3.9577 billion. It was more than double the growth of the entire outpatient prescription market.

Under $10 million domestic companies grew 2.47% to $3.982 billion.

Meanwhile, among the foreign affiliates, the total prescription amount of those with an average monthly prescription amount of $10 million or more fell 0.27% YoY to $2.137 billion, and those with less than $10 million had 0.26% growth to $69.47 million, satisfying to avoid a negative growth.

▲ In the aftermath of COVID-19, the outpatient market has weakened significantly, particularly foreign affiliates and top companies.
▲ In the aftermath of COVID-19, the outpatient market has weakened significantly, particularly foreign affiliates and top companies.


For the past eight months, Hanmi Pharmaceutical has maintained its lead by achieving $44.07 million in prescription performance, up 3.50% YoY.

Chong Kun Dang Pharmaceutical had $38.84 million, Pfizer $36.20 million, AstraZeneca $28.56 million, MSD $28.21 million, Novartis $26.62 million, Daewoong Pharmaceutical $25.16 million, Boehringer Ingelheim $23.73 million, HK Inno.N Corporation $21.63 million, and Yuhan Corporation $20.45 million.

Handok recorded $18.07 million, followed by Daewon Pharmaceutical $17.46 million, Dong-A ST $17.23 million, Daewoong Bio $16.63 million, and Hutecs $15.12 million.

Those who exceeded over $10 million are Celltrion by $14.92 million, Astellas $13.48 million, Jeil Pharmaceutical $13.03 million, Samjin Pharmaceutical $12.87 million, JW Pharmaceutical $12.76 million, Boryung Pharmaceutical $12.38 million, Korea United Pharm $12.28 million, Hanlim $12.06 million, LG Chem $11.99 million, GSK $11.70 million, Il Dong Pharmaceutical $11.41 million, Kyung Dong Pharmaceutical $10.64 million, and Daiichi Sankyo $10.36 million. 

For others, SK Chemicals, Huons, Bayer, Hana Pharm showed over $9 million prescription performance, and BMS, Takeda Pharmaceutical, Myungmoon Pharmaceutical, and Gilead Sciences made $8 million.

Celltrion had the highest growth rate of 32.91%, followed by Hutecs with 19.44%, LG Chem with 15.22%, and Boryung Pharmaceutical with 10.57%, making double-digit growth.

In contrast, Gilead Sciences fell 16.48%, Daewoong Pharmaceutical 16.27%, and Il dong Pharmaceutical 15.10%. 
 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.